genai / news / / Benzinga
Owkin will build end-to-end AI agents designed to operate within AstraZeneca's internal infrastructure and decision-making workflows.
Owkin will build end-to-end AI agents integrated directly into AstraZeneca's internal decision-making workflows.
KEY POINTS
- The K Pro platform combines multimodal data with agentic AI to aid pharmaceutical research and strategy.
- AstraZeneca's teams will deploy these AI agents under existing enterprise security, governance, and compliance standards.
- Ongoing collaborative diagnostic work continues under Waiv, Owkin's diagnostics division spinout.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →